SEC Filings

News

Profile

SISM Ratings for MIVT

Daily Chart

10.07.04 

MIVT: MIV THERAPEUTICS INC. – HAP COATING SUCCESSFULLY COMPLETES PORCINE CORONARY IMPLANTATION TRIALS
VANCOUVER, Oct. 7 /PRNewswire-FirstCall/ - MIV Therapeutics Inc. (MIVT:OTCBB), announced today the successful completion of the pilot in vivo Pilot Coronary Arteries Implantation Studies on its proprietary, biocompatible Hydroxyapatite (HAp) nano-film coating, designated for passive application on cardiovascular stents and other implantable medical devices. Report in HTM

09.13.04 

MIVT: MIV THERAPEUTICS HAP COATING SUCCESSFULLY COMPLETES SAFETY TRIAL
VANCOUVER, Sept. 13 /PRNewswire-FirstCall/ - MIV Therapeutics Inc. (MIVT:OTCBB), announced today the successful completion of in vivo safety studies on its proprietary, biocompatible Hydroxyapatite (HAp) nano-film coating, designated for passive application on cardiovascular stents and other implantable medical devices. The results of this study have shown that the stent coating is safe and did not cause any adverse arterial response. Report in HTM

09.08.04 

MIVT: MIV THERAPEUTICS VICE PRESIDENT NOMINATED FOR 2004 WORLD TECHNOLOGY AWARD
Sep 8, 2004 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics Inc. (OTCBB: MIVT) said that Dr. Tom Troczynski, Ph.D., Vice President of Coatings and Professor of Ceramics at The University of British Columbia, has been selected as a nominee for the 2004 World Technology Award in Energy at this year's World Technology Awards, being held in association with NASDAQ (OTCBB: NDAQ), Microsoft (NASDAQ: MSFT), and Time Warner's (NYSE: TWX) Time Magazine, Science magazine, and CNN. Report in HTM

08.30.04 

MIVT: MIV THERAPEUTICS INC FILES SEC FORM 10KSB, ANNUAL REPORT
Annual report under Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the fiscal year ended: May 31, 2004 Report in HTM

06.28.04 

MIVT: MIV THERAPEUTICS INC. COMPLETES SIGNIFICANT BIOCOMPATIBILITY MILESTONES FOR HAP COATING TECHNOLOGY
VANCOUVER, Jun 28, 2004 /PRNewswire-FirstCall via COMTEX/ -- MIV Therapeutics Inc. (OTCBB:MIVT), announced today that it has successfully completed the full range of biocompatibility studies on its proprietary, biocompatible hydroxyapatite (HAp) ultra-thin coating technology. The coating is designated for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. Toxikon Corporation, Bedford, MA, was commissioned by MIVT to perform the complete range of 12 biocompatibility tests which are summarized:Report in HTM

06.23.04 

MIVT: MIV THERAPEUTICS PRESENTS STENT COATING AT 7TH WORLD BIOMATERIALS CONGRESS
NEW YORK Jun 23, 2004 (financialwire.net via COMTEX) - (FinancialWire) MIV Therapeutics Inc. (OTCBB: MIVT) said its proprietary, biocompatible Hydroxyapatite (HAp) ultra- thin coating technology for passive and drug-eluting applications on cardiovascular stents and other implantable medical devices was presented by MIVT at the 7th World Biomaterials Congress in Sydney, Australia, May 17-21, 2004. Report in HTM

06.21.04 

MIVT: MIV THERAPEUTICS GAINS 7.32% FRIDAY AFTER INDEPENDENT RESEARCH NOTE
NEW YORK Jun 21, 2004 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics, Inc. (OTCBB: MIVT; Berlin: MIV1) gained 7.32% to close at $0.44, after rising to $0.47 intraday, on volume of 31,263 Friday, after Ernest C. Schlotter, analyst at Investrend affiliate SISM Research, reiterated his Buy Recommendation for MIV Therapeutics, Inc. (OTCBB: MIVT; Berlin: MIV1), with a 12-month price target of $1.50. Report in HTM

06.18.04 

MIVT: MIV THERAPEUTICS REITERATED AT BUY WITH $1.50 TARGET, BY INVESTREND AFFILIATES SISM RESEARCH
NEW YORK Jun 18, 2004 (financialwire.net via COMTEX) -- (FinancialWire) (Investrend Research Syndicate) Ernest C. Schlotter, analyst at Investrend affiliate SISM Research, has reiterated his Buy Recommendation for MIV Therapeutics, Inc. (OTCBB: MIVT; Berlin: MIV1), with a 12-month price target of $1.50. Summary in PDF

06.17.04 

MIVT: MIV THERAPEUTICS BIOCOMPATIBLE STENT COATING SUCCESSFULLY COMPLETES PYROGEN TRIAL
VANCOUVER, June 17 /PRNewswire-FirstCall/ - MIV Therapeutics Inc. (MIVT:OTCBB), announced today that its proprietary Hydroxyapatite (HAp) ultra-thin "passive" stent coating has successfully passed the Rabbit Pyrogen Test (Material Mediated) - ISO confirming that the coating is non-pyrogenic and does not induce fever. Report in HTM

06.10.04 

MIVT: MIV THERAPEUTICS INC. RETAINS STRATEGIC GROWTH AS INVESTOR RELATIONS ADVISOR
JUNE 3, VANCOUVER, June 10 /PRNewswire-FirstCall/ - MIV Therapeutics Inc. (MIVT:OTCBB) a company developing the next generation of coatings for drug delivery on stents and medical devices is pleased to announce it has retained the services of Strategic Growth International Inc. (SGI), to provide global exposure to the investment community. Report in HTM

06.03.04 

MIVT: MIV THERAPEUTICS TRADES UP 18.60% ON 2X AVERAGE VOLUME.
JUNE 3, 2004 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics traded up 18.60%, to close at $0.51, on volume of 358,735 Wednesday, approximately two times its average volume of 186,519. MIV Therapeutics is covered by Investrend Research affiliate SISM Research's analyst, Ernest C. Schlotter. On September 22, 2003, Schlotter initiated coverage with a "Buy" rating and a $1.50 target, which was reiterated October 19. SISM Research is distributed by the Investrend Research Syndicate.

06.01.04 

MIVT: US PATENT ISSUED FOR DRUG ENCAPSULATION APPLICATION OF MIV THERAPEUTICS’ BIOCOMPATIBLE DRUG ELUTING COATING TECHNOLOGY. VANCOUVER, June 1 /PRNewswire-FirstCall/ - MIV Therapeutics Inc. (MIVT:OTCBB) is pleased to announce today that the United States Patent and Trademark Office has awarded The University of British Columbia (UBC) a patent relating to MIVT's licensed biocompatible hydroxypatite (HAp) coating technology. MIVT has the exclusive worldwide license from UBC to use and sublicense the HAp coating technologies for the development, manufacture and sale of coated stents and other implantable medical devices as drug delivery systems. Report in HTM

04.26.04 

MIVT: MIV THERAPEUTICS WELCOMES DR. KEON, MEDICAL ADVISOR AND CHAIRMAN OF THE SCIENTIFIC ADVISORY BOARD
VANCOUVER, Apr 26, 2004 /PRNewswire-FirstCall via COMTEX/ -- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1:BE) is pleased to announce that Dr. Wilbert Keon, O.C., M.D., F.R.C.S.(C) has accepted the Company's invitation to act as Medical Advisor and as Chairman of the Scientific Advisory Board. Report in PDF

04.21.04 

MIVT: MIV THERAPEUTICS ANNOUNCES AN ADDITIONAL $700,00 PRIVATE PLACEMENT COMPANY RAISES MORE THAN $3 MILLION IN MARCH AND APRIL, 2004
VANCOUVER, BC, Apr 21, 2004 /PRNewswire-FirstCall via COMTEX/ -- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1.BE: Berlin) announced today that it has raised additional funds necessary for completion of the next stage of its research and development program leading towards commercialization of its proprietary biocompatible coating technology developed for cardiovascular stents and other medical devices. Report in PDF

03.30.04 

MIVT: HEMOLYSIS TEST PRODUCES SUCCESSFUL RESULTS FOR MIV THERAPEUTIC’S ULTRA-THIN HYDROXYAPATITE COATING TECHNOLOGY
VANCOUVER, Mar 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1.BE: Berlin), announced today that its proprietary, biocompatible Hydroxyapatite (Hap) ultra-thin coating for passive and drug- eluting application on cardiovascular stents and other implantable medical devices has passed another significant biocompatibility test, the Hemolysis - Rabbit Blood - Test (ISO). Report in PDF

03.25.04 

MIVT: VFINANCE ISSUES REPORT ON DRUG-ELUTING STENT TECHNOLOGY
NEW YORK--(BUSINESS WIRE)--March 25, 2004--vFinance Investments, Inc. (OTCBB:VFIN), a leading financial services firm providing research, investment banking and brokerage services to corporate, institutional and private clients, has released a sector report analyzing the impact Drug-Eluting Stent (DES) technology will have on the medical device industry. The report identifies those firms that have the most to gain and lose for the adoption of DES. Report in HTM

03.24.04 

MIVT: MIV THERAPEUTICS ULTRA-THIN HYDROXYAPATITE COATING TECHNOLOGY FOR CARDIOVASCULAR STENTS SUCCESSFULLY COMPLETES KEY SYSTEMIC INJECTION TEST
VANCOUVER, Mar 24, 2004 /PRNewswire-FirstCall via COMTEX/ -- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1.BE: Berlin) announced today that the Company's proprietary Hydroxyapatite (Hap) ultra-thin coating technology has successfully passed the Systemic Injection Test (ISO), an important milestone on the path to commercialization. MIV Therapeutics is developing a line of "next generation", biocompatible coatings for stents and drug delivery systems for the treatment of cardiovascular disease. The technology is an attractive alternative to the bare-metal stent and could provide a significant benefit to the population who cannot afford drug-eluting stents. The technology also has applications for non-vascular disorders. Report in PDF

03.24.04 

MIVT: MIV THERAPEUTICS ULTRA-THIN HYDROXYAPATITE COATING TECHNOLOGY FOR CARDIOVASCULAR STENTS SUCCESSFULLY COMPLETES KEY SYSTEMIC INJECTION TEST
VANCOUVER, Mar 24, 2004 /PRNewswire-FirstCall via COMTEX/ -- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1.BE: Berlin) announced today that the Company's proprietary Hydroxyapatite (Hap) ultra-thin coating technology has successfully passed the Systemic Injection Test (ISO), an important milestone on the path to commercialization. MIV Therapeutics is developing a line of "next generation", biocompatible coatings for stents and drug delivery systems for the treatment of cardiovascular disease. The technology is an attractive alternative to the bare-metal stent and could provide a significant benefit to the population who cannot afford drug-eluting stents. The technology also has applications for non-vascular disorders. Report in PDF

03.22.04 

MIVT: MIV THERAPEUTICS ANNOUNCES $2.34 MILLION PRIVATE PLACEMENT
VANCOUVER, Mar 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1.BE: Berlin) announced today that it has raised funds necessary for completion of the next stage of its research and development program leading towards commercialization of its proprietary biocompatible coating technology developed for cardiovascular stents and other medical devices. Report in PDF

03.08.04 

MIVT: MIV THERAPEUTICS GAINS 16.67% ON 3X VOLUME AFTGER ‘PERFECT’ SCORE FOR STENT COATING
Mar 9, 2004 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 16.67% Monday, closing at $0.80, on volume of 720,831, more than three times its average volume, after the company said its proprietary ultra-thin coating achieved another milestone by successfully passing an independent assessment of cytotoxicity (biological reactivity) of Hydroxyapatite (HAp), a coating material which is expected to become the coating of choice for passive and drug eluting applications on cardiovascular stents and other medical devices. Report in PDF

03.08.04 

MIVT: MIV THERAPEUTICS ULTRA-THIN HYDROXYAPATITE COATING SCORES PERFECT RESULT DURING BIOLOGICAL REACTIVITY (CYTOTOXICITY) TEST
TORONTO, March 8 /PRNewswire-FirstCall/ - MIV Therapeutics Inc. (MIVT:OTCBB & MIV1.BE: Berlin) is pleased to announce its proprietary ultra-thin coating achieved another milestone by successfully passing an independent assessment of cytotoxicity (biological reactivity) of Hydroxyapatite (HAp), a coating material which is expected to become the coating of choice for passive and drug eluting applications on cardiovascular stents and other medical devices. Report in HTML

03.02.04 

MIVT: MIV THERAPEUTICS GAINS 25.93% ON 9X AVERAGE VOLUME
Mar 2, 2004 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 25.93% Monday on volume of 1,569,281, about nine times its average volume of 164,841, closing at $0.68. MIV Therapeutics is covered by Investrend Research affiliate SISM Research's analyst, Ernest C. Schlotter. On September 22, 2003, Schlotter initiated coverage with a "Buy" rating and a $1.50 target, which was reiterated October 19. SISM Research is distributed by the Investrend Research Syndicate. Report in PDF

03.01.04 

MIVT: MIV THERAPEUTICS IS FEATURED BY SPECIAL SITUATIONS ANALYST Investor Alert: Biotech Firm Developing Major Cardiac Device Breakthrough. Introducing unique biocompatible coatings for stents in the treatment of cardiovascular disease – new applications are designed to revolutionize multibillion market for cardiac medical devices. Company expecting results of crucial trials – this year. Report in PDF

02.26.04 

MIVT: MIV THERAPEUTIC’S R&D TEAM MAKES IMPACT ON SCIENCE OF BIOMATERIALS
VANCOUVER, Feb. 26 /PRNewswire-FirstCall/ - Chairman of The Board and Chief Executive Officer of MIV Therapeutics Inc. (MIVT:OTCBB & MIV.BE: Berlin) announced today that the MIVT R&D team, in collaboration with the UBC team of scientists, will present three papers at the 7th World Biomaterials Congress (http://www.tourhosts.com.au/biomaterials/invit.html) in Sydney, Australia, May 17-21, 2004. One of the papers relates directly to the revolutionary MIVT technology for HAp coated stents, and is titled "Nanoporous Calcium Phosphate Thin Coatings for Stents" (click here for full text of the extended abstract of the paper). The second paper is titled "Mesoporous Bioglass Films by Sol- Gel" (abstract), and the third paper relates to HAp-based composite materials" Report in HTM

02.11.04 

MIVT: FIRST PHASE OF MIV THERAPEUTICS CANADIAN R&D PROGRAM IS SUCCESS
Feb 11, 2004 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics (OTCBB: MIVT; BSE: MIV; Frankfurt: MIV1) said it has successfully completed the first phase of its Hydroxyapatite (HA) Drug-Eluting Stent Coating R&D Program sponsored in part by the Canadian Government. The University of British Columbia has submitted its final report to the Natural Sciences and Engineering Research Council of Canada (NSERC) which provided a grant in support of the research program entitled "Functionally Gradient Calcium Phosphate Coatings for Stents." Report in PDF

02.10.04 

MIVT: MIV THERAPEUTICS SUCCESSFULLY COMPLETES GOVERNMENT -SPONSORED DRUG-ELUTING STENT COATING R&D PROGRAM
VANCOUVER, British Columbia, Feb 10, 2004 (Canada NewsWire via COMTEX) -- MIV Therapeutics Inc. (OTC Bulletin Board: MIVT; BSE: MIV; Frankfurt: MIV1) is pleased to announce that it has successfully completed the first phase of its Hydroxyapatite (HA) Drug-Eluting Stent Coating R&D Program sponsored in part by the Canadian Government. The University of British Columbia has submitted its final report to the Natural Sciences and Engineering Research Council of Canada (NSERC) which provided a grant in support of the research program entitled "Functionally Gradient Calcium Phosphate Coatings for Stents." The research activities were conducted by the University of British Columbia, UBCeram -- Metals and Materials Engineering, in close cooperation with MIVT's R&D team, under a Collaborative Research and Development Agreement. Report in PDF

02.03.04 

MIVT: MIV THERAPEUTICS CLOSES UP 11.11% ON 6X AVERAGE VOLUME
Feb 3, 2004 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics (OTCBB: MIVT) traded up 11.11% Monday to close at $0.60, on volume of 796,677, approximately six times its average volume of 127,000. MIV Therapeutics is covered by Investrend Research affiliate SISM Research's analyst, Ernest C. Schlotter. On September 22, 2003, Schlotter initiated coverage with a "Buy" rating and a $1.50 target, which was reiterated October 19. SISM Research is distributed by the Investrend Research Syndicate. Report in PDF

02.02.04 

MIVT: MIV THERAPEUTICS CLOSES UP 22.73% ON 6X AVERAGE VOLUME
Feb 2, 2004 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics (OTCBB: MIVT) closed up 22.73% to $0.54 on volume of 709,579, approximately six times its average volume of 119,646. MIV Therapeutics is covered by Investrend Research affiliate SISM Research's analyst, Ernest C. Schlotter. On September 22, 2003, Schlotter initiated coverage with a "Buy" rating and a $1.50 target, which was reiterated October 19. SISM Research is distributed by the Investrend Research Syndicate. Report in PDF

01.20.04 

MIVT:SUCCESSFUL FATIQUE LIFE TEST CONFIRMS DURABILTY OF MIV THERAPEUTICS HYDROXYAPATITE STENT COATING
VANCOUVER, Jan 20, 2004 /PRNewswire-FirstCall via COMTEX/ -- MIV Therapeutics Inc. (MIVT:OTCBB; MIV:BSE; MIV1:Frankfurt) is pleased to announce that it has successfully completed an essential fatigue life test of its proprietary hydroxyapatite (HAp) stent coating. The test titled "In-Vitro 40 Million Cycle Accelerated Fatigue Test for Stents with MIV Therapeutics' HAp Coating" was conducted to evaluate the mechanical integrity and bonding properties of MIVT's ultra-thin biocompatible coating. Report in PDF

01.20.04 

MIVT:SUCCESSFUL TATIQUE LIFE TEST CONFIRMS DURABILTY OF MIV THERAPEUTICS HYDROXYAPATITE STENT COATING
VANCOUVER, Jan 20, 2004 /PRNewswire-FirstCall via COMTEX/ -- MIV Therapeutics Inc. (MIVT:OTCBB; MIV:BSE; MIV1:Frankfurt) is pleased to announce that it has successfully completed an essential fatigue life test of its proprietary hydroxyapatite (HAp) stent coating. The test titled "In-Vitro 40 Million Cycle Accelerated Fatigue Test for Stents with MIV Therapeutics' HAp Coating" was conducted to evaluate the mechanical integrity and bonding properties of MIVT's ultra-thin biocompatible coating. Report in PDF

12.18.03 

MIVT: MIV THERAPEUTICS SHARES EXPLODE ON MILESTONES REPORT
Dec 18, 2003 (financialwire.net via COMTEX) -- (FinancialWire) The shares of MIV Therapeutics (OTCBB: MIVT) leapt 35.48% to close at $0.42, on volume of 217,000, three times its average, Wednesday after announcing it is meeting the critical path objectives of its proprietary hydroxyapatite (HAp) stent coating Research and Development (R&D) program. Report in PDF

12.17.03 

MIVT: MIV THERAPEUTICS’ HYDROXYAPATITE STENT COATING ACHIEVES SCIENTIFIC MILESTONES ON SCHEDULE
VANCOUVER, Dec 17, 2003 /PRNewswire-FirstCall via Comtex/ -- MIV Therapeutics Inc. (MIVT:OTCBB; MIV:BSE; MIV1: Frankfurt) is pleased to announce it is meeting the critical path objectives of its proprietary hydroxyapatite (HAp) stent coating Research and Development (R&D) program.Report in PDF

11.04.03 

MIVT: MIV THERAPEUTICS WELCOMES DR. ARUN CHOCKALINGAM SPEICAL ADVISOR SCIENTIFIC & INTERNATIONAL AFFAIRS
VANCOUVER, Nov 4, 2003 /PRNewswire-FirstCall via COMTEX/ -- MIV Therapeutics Inc. (MIVT:OTCBB & MIV1:FSE) is pleased to announce that Dr. Arun Chockalingam, BE, MS, PhD, FACC, FACEP has accepted our invitation to act as Special Advisor on Scientific & International Affairs. Report in PDF

10.30.03 

MIVT: MIV THERAPEUTICS INC. LISTED ON THE FRANFURT STOCK EXCHANGE
VANCOUVER, Oct 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- MIV Therapeutics Inc. (MIVT.OB :OTC BB) is pleased to announce the Company's listing application has met all admission requirements and its Regulation S stock has been accepted for listing on the Frankfurt Stock Exchange (Frankfurt WKN: 911285, MIV1.FSE). MIVT will continue to trade on the NASDAQ OTC Bulletin Board. Report in PDF

10.17.03 

MIVT: MIV THERAPEUTICS TRADES NEARLY 2X VOLUME AFTER REPORT
Oct 17, 2003 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics, Inc. (OTCBB: MIVT; BE: MIV) traded 109,500 shares, almost twice its average volume of 62,992 following the reiteration of a "Buy" rating and 6-month price target of $1.50 by Investrend affiliate SISM Research following the company's issuance of its Q1FY2004 financial results. Report in PDF

10.16.03 

MIVT: BUY RATING, $1.50 TARGET REITERATED FOR MIV THERAPEUTICS
We have reiterated our Buy rating and 6-month price target of $1.50 for MIV Therapeutics, Inc. following the Company's issuance of its Q1FY2004 financial results. MIV Therapeutics reported financial results for Q1FY2004 with a net loss for the quarter of $689,565 or ($0.03) per share compared with a net loss of $722,630 or ($0.04) per share for the same period one year ago. We estimated, for Q1FY04, a net loss of $530,000 or ($0.02) per share. The Company incurred an operating loss for the quarter, primarily because of research and development concerning its proprietary coating technology, animal trials and general administration costs. During the three months ended August 31, 2003, MIV Therapeutics focused on continuing research and development of new therapeutic technologies and on its biocompatible coating for stent and drug delivery systems. During this period of time, the Company initiated the transfer of technology from the University of British Columbia to its own premises with a focus on the introduction of proper process controls and volume production. Report in PDF

10.12.03 

MIVT: MIV THERAPEUTICS FEATURED ON EURONEWS TV MONDAY
Oct 12, 2003 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics Inc. (OTCBB: MIVT) will be featured on EuroNews Television, reaching over 150 million households, Monday, October 13, between 11 p.m. and 11:20 p.m.,Central European Time. Report in PDF

10.06.03 

MIVT: ANALYST REPORT ON MIV THERAPEUTICS FETURED IN ‘THE STENTING NEWSLETTER’
Oct 6, 2003 (financialwire.net via COMTEX) -- (FinancialWire) “The Stenting Newsletter," a global compilation of cardiovacular-related news issued by leading public companies such as Edwards Lifesciences Corp. (NYSE: EW), Medtronic (NYSE: MDT) and Thoratec Corp. (NASDAQ: THOR), as well as worldwide conferences and seminars, features the analyst report on MIV Therapeutics, Inc. (OTCBB: MIVT) in its October 6 edition. Report in PDF

09.25.03 

MIVT: MIV THERAPEUTICS GETS MILESTONE REPORT
Sep 25, 2003 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics Inc. (OTCBB: MIVT:OTCBB; BE: MIV) has received a mid-point milestone interim progress report from the University of British Columbia (UBC) on the development of its proprietary HAp (hydroxyapatite) multi-layer coating with drug-eluting capabilities.ave reiterated our Buy rating and 6-month price target of $1.50 for MIV Therapeutics Report in PDF

09.16.03 

09.16.03 

MIVT: INITIAL COVERAGE WITH A BUY RATING
MIV Therapeutics Inc.’s corporate mission is to become a world leader in the development of coatings for stents and drug delivery systems for the treatment of cardiovascular disease (with an emphasis on reducing restenosis) and for localized drug delivery to other diseased organs of the body. MIVT is in late stage development of its unique proprietary hydroxyapatite coating technology, which is covered by patents filed by the Company’s strategic partner, the University of British Columbia. This HAp coating technology could revolutionize the current $2.6 billion coronary stent market. MIVT’s HAp coating is a unique nanofilm technology that is different from the polymers currently being developed and offered by the industry for stent drug delivery systems. The enormous potential of this industry is shown in the stock valuation of Angiotech (NASDAQ:NM ANPI), a company with a $1.78 billion market cap, something that was achieved as an R&D company with a focus on developing polymer-based coatings for stent drug delivery systems. MIVT’s current low $15.6m market capitalization offers a significant upside and heavily discounts the potential for success in both animal and clinical trials. If these trials prove to be successful, we believe MIVT’s stock will rise significantly. Summary in PDF